AFPL-67. Zoledronic acid safety and efficacy over 5 years in post-menopausal osteoporosis (2007)
Devogelaer, J, Burckhardt, P, Meunier, P, Kaufman, J, Lippuner, K, Body, J, ...
AFPL-67. Zoledronic acid safety and efficacy over 5 years in post-menopausal osteoporosis (2007)
DEVOGELAER, JP, BURCKHARDT, P, MEUNIER, P, Kaufman, Jean, LIPPUNER, K, BODY, JJ, ...
Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis (2007)
Devogelaer, J. P., Brown, J. P., Burckhardt, P., Meunier, P. J., Goemaere, S., Lippuner, K., ...
In a 5-year study involving 119 postmenopausal women, zoledronic acid 4 mg given once-yearly for 2, 3 or 5 years was well tolerated with no evidence of excessive bone turnover reduction or any safety...
Zoledronic acid safety and efficacy over 5 years in post-menopausal osteoporosis (2006)
DEVOGELAER, JP, BURCKHARDT, P, MEUNIER, P, Kaufman, Jean, LIPPUNER, K, BODY, JJ, ...
Zoledronic acid safety and efficacy over 5 years in postmenopausal osteoporosis (2006)
DEVOGELAER, JP, BURCKHARDT, P, MEUNIER, P, Kaufman, Jean, LIPPUNER, K, BODY, JJ, ...
Lippuner, K., Casez, J. P., Takkinen, R., Descoeudres, C., Jaeger, Ph.
Background After EDTA-induced hypocalcaemia, healthy volunteers treated with diltiazem display more severe hyperparathyroidism than subjects on felodipine studied under identical conditions....
Hess, B., Lippuner, K., Takkinen, R., Villiger, L., Ackermann, D., Jaeger, P.
The calciuric response after an oral calcium load (l000 mg elemental calcium together with a standard breakfast) was studied in 13 healthy male controls and 21 recurrent idiopathic renal calcium...